ERBB2 and breast cancer: Interestingly, in patients receiving targeted therapy alone (i.e., trastuzumab and pertuzumab) approximately 17% of patients had pathologic complete response, demonstrating that dual HER2 inhibition alone may elicit remarkable responses in HER2-positive breast cancers [17].